Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations--an unusual encounter--a case report.
Dapsone is a drug of choice in the treatment of leprosy. In addition it is very useful in the treatment of many other dermatological conditions. The "dapsone-induced hypersensitivity" is not unknown. However, to the best of our knowledge, pulmonary eosinophilia induced by dapsone without any cutaneous allergic manifestation has not been reported in leprosy patients. Pulmonary eosinophilia (Loeffler's syndrome) induced by dapsone without cutaneous manifestation has been reported in a non leprosy patient by Janier et al. We report a case of pulmonary eosinophilia associated with dapsone therapy in a patient with lepromatous leprosy without allergic cutaneous manifestations and our experience in the management of this patient.
Arunthathi
S
S
Department of Medicine, Schieffelin Leprosy Research and Training Center, Karigiri, Tamil Nadu, India.
Raju
S
S
D003622:Dapsone / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004804:Eosinophils; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011657:Pulmonary Eosinophilia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis
D007917:Leprostatic Agents; D003622:Dapsone